Short Interest Coverage: Could SANUWAVE HEALTH INCORPORATED (OTCMKTS:SNWV) Go Down After Its Newest Short Interest Report?

November 16, 2016 - By Linda Rogers   ·   0 Comments

Short Interest Coverage: Could SANUWAVE HEALTH INCORPORATED (OTCMKTS:SNWV) Go Down After Its Newest Short Interest Report?

The stock of SANUWAVE HEALTH INCORPORATED (OTCMKTS:SNWV) registered a decrease of 84.56% in short interest. SNWV’s total short interest was 24,500 shares in November as published by FINRA. Its down 84.56% from 158,700 shares, reported previously. About 3,000 shares traded hands. SANUWAVE Health, Inc. (OTCMKTS:SNWV) has risen 350.00% since April 14, 2016 and is uptrending. It has outperformed by 345.31% the S&P500.

SANUWAVE Health, Inc. is an acoustic pressure shock wave technology firm using a system of noninvasive, high-energy, acoustic pressure shock waves for indications, such as regenerative medicine and other applications. The company has a market cap of $24.16 million. The Firm is focused on regenerative medicine utilizing noninvasive , acoustic pressure shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of skin, musculoskeletal tissue and vascular structures. It currently has negative earnings. The Company’s lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers.

SNWV Company Profile

SANUWAVE Health, Inc., incorporated on May 6, 2004, is an acoustic pressure shock wave technology firm using a system of noninvasive, high-energy, acoustic pressure shock waves for indications, such as regenerative medicine and other applications. The Firm is focused on regenerative medicine utilizing noninvasive (extracorporeal), acoustic pressure shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of skin, musculoskeletal tissue and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers, which was subject to two double-blinded, randomized Phase III clinical studies. The Company’s portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, enabling to restore the body’s normal healing processes and regeneration. The Firm sells the European Conformity Marking (CE Mark) devices and accessories in Europe, Canada, Asia and Asia/Pacific. The Firm operates in Europe, Canada, Asia and Asia/Pacific.

More notable recent SANUWAVE Health, Inc. (OTCMKTS:SNWV) news were published by: Seekingalpha.com which released: “SANUWAVE Health, Inc. (SNWV) CEO Kevin Richardson on Q2 2016 Results …” on August 15, 2016, also Globenewswire.com with their article: “SANUWAVE Health to Showcase Its Shock Wave Technology at the 2016 Biofilm …” published on July 18, 2016, Globenewswire.com published: “SANUWAVE Health Signs Strategic Agreement With Premier Shockwave to Manage …” on July 22, 2014. More interesting news about SANUWAVE Health, Inc. (OTCMKTS:SNWV) were released by: Globenewswire.com and their article: “SANUWAVE Health Reports Record Year to Date Order Book for orthoPACE and …” published on August 30, 2016 as well as Globenewswire.com‘s news article titled: “SANUWAVE Health Submits de novo Petition for FDA Review and Classification of …” with publication date: August 11, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Linda Rogers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>